AKI linked to CKD, kidney function decline for patients with leukemia, lymphoma
Click Here to Manage Email Alerts
Patients who developed AKI during hospitalization with hematologic malignancy experienced a significantly increased risk for kidney function decline and chronic kidney disease in the following year.
“This large population-based cohort study is among the first to explore the relationship between AKI and kidney function outcomes in patients with newly diagnosed acute leukemia or lymphoma,” Heather P. May, PharmD, of the Mayo Clinic in Rochester, and colleagues wrote. “Kidney function is an important determinant of eligibility for preferred chemotherapy, hematopoietic cell transplantation and clinical trials and thus its preservation plays a vital role in optimizing malignancy outcomes.”
With this in mind, researchers assessed 1-year kidney outcomes in 1,064 participants who were hospitalized within 3 weeks of malignancy diagnosis (AKI occurred in 33% of study population; 70% of episodes occurred within 48 hours of hospitalization).
Findings showed that, compared with patients who did not have AKI, those who did were more likely to experience a 30% or greater decline in eGFR (hazard ratio [HR] = 2.7), as well as to develop incident chronic kidney disease (HR = 2.2). The resulting eGFR decline was also shown to increase 1-year mortality risk (HR = 2.1).
“[These] results help to identify individuals at high risk for poor outcomes who stand to benefit most from action to protect and preserve kidney function,” May and colleagues concluded. “Further research is needed to determine interventions that may mitigate deleterious consequences of AKI in this unique subset of patients.”
Collapse
Read more about
Click Here to Manage Email Alerts